Pharmaniaga Ponders Strategy

Because of losses incurred over the last twelve months, Malaysian generic medicine and healthcare company Pharmaniaga is reconsidering its operations in China. Escalating costs and less than acceptable sales have been attributed to changes in China's regulatory environment and maturation of distribution channels. BMI does not believe that this development accurately reflect the opportunities available in China and is of the view that perhaps Pharmaniaga's joint venture was not structured to its ultimate benefit, hence the losses in the last financial

To read the full article, please choose one of the following options: